Systematic Search for Primary Immunodeficiency in Adults With Infections

NCT02972281 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-04-21

No results posted yet for this study

Summary

Antibody deficiencies and complement deficiencies are the most frequent Primary immunodeficiencies (PIDs) in adults, and are associated with greatly increased susceptibility to recurrent and/or severe bacterial infections - especially upper and lower respiratory tract infections and meningitis. The literature data suggest that PIDs are under-diagnosed in adults. The current European and US guidelines advocate screening adults for PIDs if they present recurrent benign especially upper and lower respiratory tract infections, or if they have experienced at least two severe bacterial infections and/or have a recurrent need for intravenous antibiotics. The objective of the demonstrate the interest of PIDs screening in adult patients who present such recurrent infections and/or after the first severe bacterial infection, especially when the patients do not present with known, etiologically relevant comorbidities.

Conditions

  • Complement Deficiency
  • Antibody Deficiency
  • Chronic Sinus Infection
  • Meningitis, Bacterial
  • Pneumonia, Bacterial
  • Otitis Media
  • Streptococcal Infection
  • Neisseria Infections
  • Haemophilus Influenza
  • Pneumococcal Infections

Interventions

BIOLOGICAL

Immunological diagnosis tests

(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...

Sponsors & Collaborators

  • Imagine Institute

    collaborator OTHER
  • Octapharma

    collaborator INDUSTRY
  • CSL Behring

    collaborator INDUSTRY
  • Laboratoire français de Fractionnement et de Biotechnologies

    collaborator INDUSTRY
  • Air Liquide SA

    collaborator INDUSTRY
  • The Binding Site Ltd

    collaborator UNKNOWN
  • University Hospital, Lille

    lead OTHER

Principal Investigators

  • Guillaume Lefevre, MD · University Hospital, Lille

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2020-03-31
Completion
2020-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02972281 on ClinicalTrials.gov